Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun…
Chinese biotech is booming, led by a generation of pioneering individuals at the forefront of science and business. A country once best known as a low-cost manufacturing destination for…
Dr Ben Zhao, Chief Executive Officer and co-founder of Haichang Biotechnology (HCBio, Haichang), represents a new paradigm in pharmaceutical innovation, bridging regulatory expertise with entrepreneurial vision. Having transitioned from a…
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with…
Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and…
Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he…
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to…
See our Cookie Privacy Policy Here
